Study rules out an antioxidant treatment for slowing the progression of Parkinson’s disease
Researchers at Mass General find no therapeutic benefit to raising the level of urate in the brain
Dr. Schwarzschild completed undergraduate training in biochemistry at Princeton University. He went on to medical, and graduate neuroscience training at Harvard Medical School to write his PhD thesis on the neurochemistry of tyrosine hydroxylase, the enzyme controlling dopamine biosynthesis. His neurology residency and Parkinson's disease (PD) fellowship training were at MGH.
Since 1996 Dr. Schwarzschild has directed the Molecular Neurobiology Laboratory at MGH, focusing on the role of three purines, adenosine, caffeine, and urate, in PD. His laboratory discovered the neuroprotective properties of adenosine A2A receptor blockers (including caffeine). His leadership of a series of international research conferences on A2A receptors in Parkinson's has helped translate our understanding of this drug target into a promising new therapy for Parkinson's patients.
Most recently, through an interdisciplinary collaboration with epidemiologists at the Harvard School of Public Health, he and his colleagues, in partnership with the Parkinson Study Group (PSG), have shown that the purine antioxidant urate is a novel biomarker that can help predict the risk of PD and its progression rate as well as being a neuroprotective agent candidate.
Dr. Schwarzschild has been the recipient of a Cotzias Fellowship from the American Parkinson's Disease Association and a Paul Beeson Physician Faculty Scholar Award. He has led disease progression studies of the PSG, a consortium of North American clinical trial sites and investigators dedicated to finding improved treatments for PD. In 2012 Dr. Schwarzschild was elected to chair the Executive Committee of the PSG, now headquartered in the MGH Neurology Department. He is a staff neurologist at MGH, working with Parkinson's patients and their families in his weekly movement disorders clinic.
Clinical Interests:
Treats:
Mass General Neurology
55 Fruit St.
Boston, MA 02114
Phone: 855-644-6387
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Schwarzschild is the principal investigator at the Molecular Neurobiology Laboratory at the MassGeneral Institute for Neurodegenerative Disease. His team of researchers investigates molecular mechanisms in Parkinson's disease in an effort to develop improved therapies for Parkinson's and related neurodegenerative diseases.
Visit Dr. Schwarzschild's Molecular Neurobiology Laboratory to read about current research.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
The Mukerji Lab for Neuroinfectious Diseases has an ongoing clinical trial for people with HIV and depression.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
Researchers at Mass General find no therapeutic benefit to raising the level of urate in the brain
What do Gaucher’s disease, gout, and amyloid plaques have in common? For researchers at Mass General, each of them may shed light on the causes and treatment of Parkinson’s disease.